We advised Stichting DOEN with its investment in Chocolatemakers, manufacturers of sustainable chocolate located in Amsterdam.

We advised BOM Capital on the sale of its shares in BioNovion to Aduro Biotech. The company, based on the Pivot Park in Oss, is the new European headquarters of Nasdaq-listed Aduro Biotech and renamed in Aduro Biotech Europe. Aduro acquired BioNovion to broaden its technological portfolio and to increase the potential of immunotherapy. BioNovion develops monoclonal antibody therapies against cancer, on the basis of their unique platform technology and expertise in the field of immune therapy of cancer.

We advised BOM Capital with its investment in Dutch Venture Initiative, a fund-of-funds aiming to boost equity investments into innovative and/or high tech early and development stage enterprises in the Netherlands.

We advised BOM Capital with its investment in Forbion III, an investment fund focusing on life sciences and biomedical technology companies.

We advised XebiaLabs in relation to the $12 million investment bij Updata Partners based in Washington D.C. XebiaLabs develops enterprise-scale Continuous Delivery and DevOps software, providing companies with the visibility, automation and control to deliver software faster and with less risk.